STAP1

Across TCGA pan-cancer cohorts, STAP1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated STAP1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STAP1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STAP1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC and LUAD are the cancer types where STAP1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.984	0.280	.017	3	view →
LUAD	DFS	Median	II,III,IV	1.000	0.713	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

STAP1–PDAC (DFS)

Open the PDAC breakdown →